NCT05520801|Unknown
Primary Hepatobiliary Cancer Cohort of Central China
CCGLC-002
The Treatment and Prognosis of Primary Hepatobiliary Cancer: A Cohort Study in Central China
Loading search results
CCGLC-002
The Treatment and Prognosis of Primary Hepatobiliary Cancer: A Cohort Study in Central China
Sponsor study identifier
observational
2,000
1 country
1
Study Start
May 1, 2020
Actual (reported)Primary Completion
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
This registry is designed as a longitudinal cohort study of patients diagnosed with primary hepatobiliary cancer in Tongji Hospital, Wuhan. This study collects the clinical-pathological features of hepatic malignant tumors and the current status of patients who received comprehensive treatment based on surgical treatment since 1998.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 1, 2020
Actual (reported)January 23, 2022
Actual (reported)August 30, 2022
Actual (reported)December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Overall Survival (OS)
Time of death will be obtained by telephone interview or medical treatment records.
From diagnosis or treatment initiation to date of death due to any cause, or last known vital status date, up to 2 years
Progression-free survival (PFS)
Patients lost for follow up or withdrawn from the study will be censored at the last disease assessment date
From treatment initiation for advanced or metastatic HCC to the first date of disease progression for any cause up to 2 years
Disease Control Rate (DCR)
The proportion of patients who had either stable disease (SD) for ≥ 6 months, a CR or PR after initiation of treatment for HCC
From treatment initiation to SD, CR or PR, up to 2 years
Duration of Response (DOR)
DOR is the duration from the first assessment of the tumor was CR or PR to the time that the first assessment for PD or date of death from any cause
From treatment initiation to PD, up to 2 years
Objective response rates (ORR)
Percentage of patients whose tumors have a complete or partial response to treatment.
Time of recurrence
From date of diagnosis until the date of cancer recurrence or date of death from any cause, whichever came first, assessed up to 10 years
Time of metastasis
From date of diagnosis until the date of cancer metastasis or date of death from any cause, whichever came first, assessed up to 10 years
Quality of Life (QoL) after treatment
From date of diagnosis until the date of cancer recurrence or date of death from any cause, whichever came first, assessed up to 10 years
Patients who diagnosed as primary hepatobiliary cancer.
Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Tissue, blood, urine, feces, ascites, bile samples
Bixiang Zhang
Tongji Hospital
Zeyang Ding
Tongji Hospital
First Submitted
January 23, 2022
First Posted
August 30, 2022
Study Start
May 1, 2020
Actual (reported)Primary Completion
December 31, 2024
Estimated (date passed)From treatment initiation to CR or PR, up to 2 years
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
December 19, 2023
Record last verified: 2023-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: